In 2021, Morales Murillo et al. published the results of another prospective single-center study that enrolled 122 patients with ER+/HER2- invasive breast cancer who were candidates for NACT based on tumor size and/or biological criteria. This evidence concerns the gene ERBB2 and neoplasm.